April 2010 Vol XXXIV Issue 4
ENDOSCOPY: OPENING NEW EYES, SERIES #3
The Evolution of Enteroscopy to Spiral EnteroscopySpiral enteroscopy has emerged as a viable alternative to balloon-assisted enteroscopy in the diagnosis and treatment of small bowel diseases. This article reviews the milestone technologies of enteroscopy, highlighting the latest developed spiral enteroscopy.
DISEASES OF THE BILIARY TRACT, SERIES #3
Sclerosing CholangitisIn this article, we discuss the causes, diagnosis, complications and treatment of Sclerosing Cholangitis.
NUTRITION ISSUES IN GASTROENTEROLOGY, SERIES #83
Reinfusion of Intestinal Secretions:A Viable Option for Select Patientsn this article, we focus on the hydration aspects of select patients with pancreatitis who develop a severe or complicated course requiring nutrition support. We also share and discuss one institution's experience of reinfusing gastric and/or pancreatobiliary secretions to maintain absorption, hydration and electrolyte status in the patient's own home environment.
A SPECIAL ARTICLE
A Review of the Pathophysiology and Treatment of Shiga Toxin Producing E. Coli InfectionThis article discusses the epidemiology of the pathogenic E. coli O157:H7 strain, presents its various clinical manifestations, identifies current diagnostic methods and outlines current treatment strategies.
A CASE REPORT
No Way OutHere, we discuss the use of endoscopic balloon dilatation to treat gastric outlet obstruction, a rare but serious side effect of chemotherapy for the treatment of gastric lymphomas.
FELLOWS CORNER
A case for you to solve.
Departments Section
Endoscopic Ultrasonography, Second Edition
The second edition Endoscopic Ultrasonography edited by Gress and Savides provides a wealth of information and practical advice for those interested in endoscopic ultrasonography. This text can be utilized by the experienced endosonographer, fellow in training, or general gastroenterology practitioner wishing to refresh and expand his or her skills and knowledge in endoscopic ultrasonography.
Curbside Consultation in IBD
This new book on inflammatory bowel diseases (IBD), called Curbside Consultation in IBD, consists of 49 short chapters, each of which asks one question (or sometimes a few) on a wide variety of IBD topics.
Gastric Acid Inhibition Use in Pediatric Cystic Fibrosis
Medications that promote gastric acid inhibition (GAI), such as H2-antagonist or proton pump inhibitor therapy, are often added to the medical regimen of patients with cystic fibrosis (CF) and pancreatic insufficiency to help improve the efficacy of pancreatic enzyme replacement therapy (PERT). However, prior studies have demonstrated that GAI in other patient populations may increase the risk of pulmonary infections, and the authors of this study evaluated if longterm GAI affected lung function as well as bacterial colonization in pediatric CF patients.
Tricyclic Antidepressant Use in Children with IBS
Functional gastrointestinal disorders (FGIDs) in children include such entities as irritable bowel syndrome, functional abdominal pain, and functional dyspepsia. Minimal research is available regarding pharmacologic treatment of these disorders. This study prospectively followed children from 6 tertiary children's hospitals across the United States.
IMMCO Diagnostics Inc. Announces the Launch of New ImmuLisaTM Celiac G+ and tTG Antibody Assays
More Sensitive, More Accurate Detection of Celiac Disease. IMMCO Diagnostics Inc. Announces the Launch of New ImmuLisaTM Celiac G+ and tTG Antibody Assays IMMCO Diagnostics is pleased to announce the introduction of ImmuLisaTM Celiac G+ antibody assays and ImmuLisaTM anti-human Tissue Transglutaminase (tTG) for the detection of antibodies in patients with Celiac disease.
Xifaxan® 550 mg Tablets Demonstrate Significant Reduction of Risk for Episodes of Overt Hepatic Encephalopathy According to Findings Published in The New England Journal of Medicine
Salix Pharmaceuticals, Ltd. announced the publication of results from the Company’s pivotal Phase 3 efficacy and safety study of XIFAXAN® (rifaximin) 550 mg tablets in The New England Journal of Medicine.
